Molecular targeted therapy by using a drug that reduces the growth and spread of cancer cells via inhibition of a specific protein is a foundation stone of precision medicine and treatment. The main objective of our research is to identify lead molecules that selectively inhibit proliferation and metastasis of cancer cells originating from colon, prostate, breast, and skin. These tumors are the four top cancer diseases in Sweden and worldwide with highest prevalence. Therefore, there is an urgent need for development of novel drugs that can cure or prolong the survival of these patients. At the initial step and as a proof of concept, we are focusing on metastatic melanoma as a model system. Furthermore, the therapeutic market of melanoma has significant unmet needs in terms of safety of drug treatment and efficacy profiles. Our research activates aim at multi-parameter lead optimization, preclinical and clinical verification to generate a safe and efficacious drug. We hope to achieve positive response of targeted therapy in clinical trials and as a new innovative strategy for cancer patients.